用于治疗溃疡性结肠炎的美沙拉嗪制剂：它们都一样吗？
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?
作者信息
Ye Bei, van Langenberg Daniel R
机构信息
Bei Ye, Daniel R van Langenberg, Department of Gastroenterology, Eastern Health, Victoria 3128, Australia.
出版信息
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):137-44. doi: 10.4292/wjgpt.v6.i4.137.
Abstract
Oral mesalazine (also known as mesalamine) is a 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission. The therapeutic effect of mesalazine occurs topically at the site of diseased colonic mucosa. A myriad of oral mesalazine preparations have been formulated with various drug delivery methods to minimize systemic absorption and maximise drug availability at the inflamed colonic epithelium. It remains unclear whether different oral mesalazine formulations are bioequivalent. This review aims to evaluate the differences between mesalazine formulations based on the currently available literature and explore factors which may influence the selection of one agent above another.
摘要
口服美沙拉嗪（也称为美沙拉明）是一种5-氨基水杨酸化合物，用于治疗轻至中度溃疡性结肠炎，在诱导和维持缓解方面具有较高的疗效。美沙拉嗪的治疗作用在病变结肠黏膜部位局部发生。已经开发了多种口服美沙拉嗪制剂，采用了各种药物递送方法，以尽量减少全身吸收并最大限度地提高药物在炎症性结肠上皮的可用性。目前尚不清楚不同的口服美沙拉嗪制剂是否具有生物等效性。本综述旨在根据现有文献评估美沙拉嗪制剂之间的差异，并探讨可能影响一种制剂优于另一种制剂选择的因素。
相似文献
1
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):137-44. doi: 10.4292/wjgpt.v6.i4.137.
2
Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Aliment Pharmacol Ther. 2011 May;33(9):996-1009. doi: 10.1111/j.1365-2036.2011.04619.x. Epub 2011 Mar 8.
3
Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Drugs. 2002;62(11):1689-705. doi: 10.2165/00003495-200262110-00010.
4
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Aliment Pharmacol Ther. 2007 Nov 1;26(9):1179-86. doi: 10.1111/j.1365-2036.2007.03471.x.
5
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Scand J Gastroenterol Suppl. 2002(236):42-7. doi: 10.1080/003655202320621445.
6
A practical guide to the management of distal ulcerative colitis.
Drugs. 1998 Apr;55(4):519-42. doi: 10.2165/00003495-199855040-00004.
7
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40. doi: 10.1111/j.1365-2036.2006.03058.x.
8
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Drugs. 2000 Apr;59(4):929-56. doi: 10.2165/00003495-200059040-00016.
9
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4.
10
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
引用本文的文献
1
Self-disassembling nanoparticles as oral nanotherapeutics targeting intestinal microenvironment.
Nat Commun. 2025 Apr 9;16(1):3365. doi: 10.1038/s41467-025-58513-y.
2
pH-Dependent Drug Delivery Systems for Ulcerative Colitis Treatment.
Pharmaceutics. 2025 Feb 10;17(2):226. doi: 10.3390/pharmaceutics17020226.
3
Orally Administrated Inulin-Modified Nanozymes for CT-Guided IBD Theranostics.
Int J Nanomedicine. 2025 Feb 18;20:2119-2131. doi: 10.2147/IJN.S497558. eCollection 2025.
4
Waterborne polyurethane nanoparticles incorporating linoleic acid as a potential strategy for controlling antibiotic resistance spread in the mammalian intestine.
Mater Today Bio. 2024 Aug 10;28:101181. doi: 10.1016/j.mtbio.2024.101181. eCollection 2024 Oct.
5
Invited commentary to immunotherapy withdrawal by step-down to mesalamine in pediatrics patients with ulcerative colitis.
JPGN Rep. 2024 Feb 5;5(2):95-96. doi: 10.1002/jpr3.12047. eCollection 2024 May.
6
Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats.
Saudi Pharm J. 2024 Jan;32(1):101910. doi: 10.1016/j.jsps.2023.101910. Epub 2023 Dec 10.
7
Natural History of Pediatric Patients With Crohn's Disease Treated With Mesalamine Therapy.
JPGN Rep. 2023 Nov 3;4(4):e379. doi: 10.1097/PG9.0000000000000379. eCollection 2023 Nov.
8
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.
Microbiome Res Rep. 2023 Sep 26;2(4):35. doi: 10.20517/mrr.2023.41.
9
Cytomegalovirus Pneumonia in Inflammatory Bowel Disease: Literature Review and Clinical Recommendations.
Infect Drug Resist. 2023 Sep 13;16:6195-6208. doi: 10.2147/IDR.S420244. eCollection 2023.
10
Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease.
EMBO Rep. 2023 Oct 9;24(10):e57084. doi: 10.15252/embr.202357084. Epub 2023 Sep 11.
本文引用的文献
1
Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse.
Aliment Pharmacol Ther. 2013 Sep;38(5):531-8. doi: 10.1111/apt.12396. Epub 2013 Jul 8.
2
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3.
3
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
4
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Am J Gastroenterol. 2011 Dec;106(12):2070-7; quiz 2078. doi: 10.1038/ajg.2011.296. Epub 2011 Sep 6.
5
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
BMC Health Serv Res. 2011 Jul 5;11:157. doi: 10.1186/1472-6963-11-157.
6
Aminosalicylates for induction of remission or response in Crohn's disease.
Cochrane Database Syst Rev. 2010 Dec 8(12):CD008870. doi: 10.1002/14651858.CD008870.
7
A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
J Med Econ. 2010 Mar;13(1):148-61. doi: 10.3111/13696990903562861.
8
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
Inflamm Bowel Dis. 2010 Sep;16(9):1567-74. doi: 10.1002/ibd.21193.
9
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Aliment Pharmacol Ther. 2009 Nov 1;30(9):908-18. doi: 10.1111/j.1365-2036.2009.04117.x. Epub 2009 Aug 12.
10
Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
World J Gastroenterol. 2009 Apr 21;15(15):1799-804. doi: 10.3748/wjg.15.1799.
Zotero 插件